InspireMD Advances with FDA Study Approval and Global Goals
Company Announcements

InspireMD Advances with FDA Study Approval and Global Goals

An update from InspireMD ( (NSPR) ) is now available.

InspireMD, Inc. announced on October 7, 2024, the FDA approval to begin the CGUARDIANS II pivotal study for their CGuard Prime 80cm Carotid Stent System. This milestone is a significant step for the company, aiming to enhance stroke prevention and carotid disease management. The study, led by esteemed vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck, will evaluate the device’s use during transcarotid revascularization procedures. This approval propels InspireMD towards its goal of market leadership in the U.S. and global expansion, while concurrently developing their next-generation TCAR Neuroprotection System, SwitchGuard NPS.

For detailed information about NSPR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInspireMD Achieves Record Q3 Revenue with CGuard Success
TheFlyInspireMD reports Q3 EPS (16c) vs (15c) last year
Catie PowersNSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App